Biotech Values

[mskatiescarletohara]

Congrats to HGSI!!!! It certainly does appear NVS is ramping up it's anti-viral arsenal and since they are marketing IDIX's Hep B abroad, along with their HEP C candidate, I would not be surprised to see NVS begin making strategic moves in treating HIV, another market that is to double in the next 5 years. It appears NVS may actually be contemplating a new SOC regimen as one is needed so desperately, VRTX, hmmmm now that would be interesting if NVS licensed VX-950.

katie...